|
Generic Name for ZYCLARA
Imiquimod 3.75%; topical cream; contains parabens.
Legal Classification:
Rx
Pharmacological Class for ZYCLARA
Immune response modifier.
Manufacturer of ZYCLARA
Medicis Pharmaceuticals Corp
|
Indications for ZYCLARA
External genital warts. Perianal warts.
Other Indications for ZYCLARA
Adult dose for ZYCLARA
Apply thin layer to warts and rub in once daily prior to bedtime; leave on for 8 hours. Wash off with mild soap and water. Continue until total clearance or for up to 8 weeks. Max one packet per application to treatment area. Interrupt if local skin reaction occurs; resume after several days or once the reaction subsides. Wash hands before/after application.
Children's dosing for ZYCLARA
Not recommended.
Warnings/Precautions for ZYCLARA
Immunosuppressed. Autoimmune conditions. Not for treating urethral, intra-vaginal, cervical, rectal or intra-anal human papilloma viral disease, xeroderma pigmentosum, superficial basal cell carcinoma. Sun sensitivity. Avoid eyes, lips, nose, mouth, mucous membranes, sun or UV light (use sunscreen daily). Do not occlude. Pregnancy (Cat.C). Nursing mothers.
Interactions for ZYCLARA
Avoid concomitant other forms of imiquimod.
Adverse Reactions for ZYCLARA
Local inflammation (eg, erythema, crusting, erosion, weeping, edema), pruritus, flaking, scaling, dryness, flu-like symptoms (eg, headache, fatigue, nausea, fever, chills, myalgia), transient increase in lesion counts; exacerbation of skin inflammatory conditions (eg, graft vs. host disease), chest pain, lymphadenopathy, hypo- or hyperpigmentation.
How is ZYCLARA supplied?
Single-use packets—28